Paradigm: Funding, Investors & Team (Sep 2026)

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare systems by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Paradigm has raised $78.0M across 1 round on record. The most recent is a Series B of $78.0M announced in Dec 2025.

Paradigm's most recent funding round on record is a Series B of $78.0M, announced in Dec 2025.

FundedIQ lists Fred Ehrsam (Founder) at Paradigm.

Paradigm is based in New York, New York, United States.

Paradigm is in the 101-250 employee band.

Paradigm's latest round of $78.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.